2 results
Approved WMORecruiting
To evaluate the efficacy based on the histological response
Approved WMOCompleted
The primary objective is to demonstrate the efficacy of AR101, a pharmaceutical-grade peanut allergen formulation, through reduction in clinical reactivity to limited amounts of peanut allergen in peanut-allergic children (ages 4-17 years, inclusive…